Neurocrine Biosciences
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Neurocrine Biosciences sits in the top decile of US sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count).
Neurocrine Biosciences: 65 sponsored US clinical trials, 12 recruiting.
Neurocrine Biosciences sponsors 65 registered US clinical trials on ClinicalTrials.gov, 12 of them currently recruiting, and 42 completed. 23 of these trials are in Phase 3-4 (later-stage) and 40 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 6 trials.
Top-decile sponsor footprint
Neurocrine Biosciences ranks in the top decile of sponsors by registered trial count (#318 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
42 of 48 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
65 total, page 1 of 2
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NCT07365462
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
NCT05226780
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
NCT05206513
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
NCT04806451
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
NCT04400331
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
NCT05859698
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
NCT05654870
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
NCT05545111
Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
NCT05301894
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
NCT05203341
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
NCT04873869
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
NCT05182476
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
NCT05165394
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
NCT05110157
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
NCT04625101
Opicapone Treatment Initiation Open-Label Study
NCT04787965
A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants
NCT04234672
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
NCT04045145
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
NCT04102579
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
NCT03891862
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
NCT03706469
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
NCT03562494
Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome
NCT03732534
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
NCT03698331
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
NCT03733496
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
NCT03530293
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
NCT03525886
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03444038
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
NCT03496870
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
NCT03359785
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
NCT03382639
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
NCT03214588
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
NCT03325010
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants
NCT03224325
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
NCT03065192
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
NCT03101293
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
NCT02879578
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 27 |
| Phase 3 | 19 |
| Phase 4 | 4 |
What is open in the Neurocrine Biosciences pipeline
12 recruiting of 65 indexed (18% open); 42 completed (65%).
Phase mix: 23 late (III/IV) vs 40 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Neurocrine Biosciences: open-pipeline peers nationwide
Peers matched on 65 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
Neurocrine Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 65 trials (± recruiting share)
- BeiGene · 65 trials · 14% recruiting
- Glaxo Wellcome · 65 trials · 0% recruiting
- LEO Pharma · 65 trials · 5% recruiting
- Women and Infants Hospital of Rhode Island · 65 trials · 22% recruiting
Sponsors near 18% open enrollment (± trial volume)
- University of California, San Diego · 18% recruiting · 775 trials
- Thomas Jefferson University · 18% recruiting · 292 trials
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Florida Atlantic University · 19% recruiting · 27 trials
Related
What to do with this Neurocrine Biosciences page
65 registered trials is a research-attention snapshot, not an endorsement of Neurocrine Biosciences or any single study.
- 12 of Neurocrine Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Neurocrine Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Neurocrine Biosciences pipeline card: 65 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.